Screening approach by a combination of computational and in vitro experiments: identification of fluvastatin sodium as a potential SIRT2 inhibitor
Related Experiment Video
Updated: Jun 25, 2025
Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
Jin Yang1, Hanxun Wang1, Jiale Liu2
1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenhe District, 103 Wenhua Road, Shenyang, 110016, People's Republic of China.
Background:
Sirtuins (SIRTs) are NAD+-dependent deacetylases that play various roles in numerous pathophysiological processes, holding promise as therapeutic targets worthy of further investigation. Among them, the SIRT2 subtype is closely associated with tumorigenesis and malignancies. Dysregulation of SIRT2 activation can regulate the expression levels of related genes in cancer cells, leading to tumor occurrence and metastasis.
Methods:
In this study, we used computer simulations to screen for novel SIRT2 inhibitors from the FDA database, based on which 10 compounds with high docking scores and good interactions were selected for in vitro anti-pancreatic cancer metastasis testing and enzyme binding inhibition experiments. The results showed that fluvastatin sodium may possess inhibitory activity against SIRT2. Subsequently, fluvastatin sodium was subjected to molecular docking experiments with various SIRT isoforms, and the combined results from Western blotting experiments indicated its potential as a SIRT2 inhibitor. Next, molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations were performed, revealing the binding mode of fluvastatin sodium at the SIRT2 active site, further validating the stability and interaction of the ligand-protein complex under physiological conditions.
Results:
Overall, this study provides a systematic virtual screening workflow for the discovery of SIRT2 activity inhibitors, identifies the potential inhibitory effect of fluvastatin sodium as a lead compound on SIRT2, and opens up a new direction for developing highly active and selectively targeted SIRT2 inhibitors.
Insights
Researchers identified fluvastatin sodium as a potential SIRT2 inhibitor using computer simulations and in vitro experiments. This discovery offers a new avenue for developing targeted therapies against cancer metastasis.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Sirtuins (SIRTs) are NAD+-dependent deacetylases involved in various pathophysiological processes.
- SIRT2 is implicated in tumorigenesis and cancer metastasis.
- Dysregulation of SIRT2 impacts cancer cell gene expression, promoting tumor development.
Purpose of the Study:
- To identify novel SIRT2 inhibitors using computational screening.
- To evaluate the anti-cancer metastasis potential of identified compounds.
- To validate fluvastatin sodium as a potential SIRT2 inhibitor.
Main Methods:
- Virtual screening of FDA drug database using computer simulations.
- In vitro anti-pancreatic cancer metastasis assays.
- Enzyme binding inhibition experiments.
- Molecular docking, molecular dynamics (MD) simulations, and binding free energy calculations.
- Western blotting experiments.
Main Results:
- Fluvastatin sodium demonstrated potential inhibitory activity against SIRT2.
- Molecular simulations confirmed fluvastatin sodium's stable binding at the SIRT2 active site.
- The study established a workflow for discovering SIRT2 inhibitors.
Conclusions:
- Fluvastatin sodium is a promising lead compound for developing selective SIRT2 inhibitors.
- This research opens new therapeutic strategies targeting SIRT2 in cancer.
- The findings support further investigation of fluvastatin sodium for cancer treatment.
